Understanding how CEACAM1 affects B-cell signaling and treatment in mantle cell lymphoma
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma
This study is looking at a protein called CEACAM1 that might affect how certain immune cells work in people with mantle cell lymphoma, especially those who aren't responding well to treatments like ibrutinib, to find new ways to help improve their treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10880440 on NIH RePORTER |
What this research studies
This research investigates the role of CEACAM1, a protein found on the surface of certain immune cells, in the signaling pathways of B-cells that contribute to mantle cell lymphoma (MCL). By using advanced techniques like CRISPR-Cas9 and gene expression profiling, the study aims to uncover how CEACAM1 influences the effectiveness of current treatments, particularly in patients who do not respond to standard therapies like ibrutinib. The goal is to identify new therapeutic targets that could improve outcomes for MCL patients. Patients may benefit from insights that could lead to more effective treatment strategies tailored to their specific cancer biology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with mantle cell lymphoma, particularly those who have not responded to standard treatments.
Not a fit: Patients with other types of non-Hodgkin lymphoma or those who do not have mantle cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with mantle cell lymphoma.
How similar studies have performed: Previous research has shown promising results in targeting B-cell receptor signaling in other B-cell malignancies, suggesting potential for success in this area as well.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Ngo, Vu Nguyen — Beckman Research Institute/city of Hope
- Study coordinator: Ngo, Vu Nguyen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.